Dr. Uzzo on Biomarker Development for RCC

Robert G. Uzzo, MD
Published: Friday, Nov 10, 2017



Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).

There are currently no biomarkers for patients with RCC, states Uzzo. Researchers are investigating immunohistochemical stains as a potential biomarker, but further research is needed.

According to Uzzo, the most effective biomarker will be easily collected and will have a high sensitivity and specificity.



Robert G. Uzzo, MD, chair, Surgical Oncology, G. Willing "Wing" Pepper Chair in Cancer Research, senior vice president, Physician Services, president, Fox Chase Cancer Center Medical Group, Inc., professor of surgery, Temple University Health System, Fox Chase Cancer Center, discusses biomarker development for patients with renal cell carcinoma (RCC).

There are currently no biomarkers for patients with RCC, states Uzzo. Researchers are investigating immunohistochemical stains as a potential biomarker, but further research is needed.

According to Uzzo, the most effective biomarker will be easily collected and will have a high sensitivity and specificity.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x